(Q38187365)

30 August 2017

title

Current role of FDG PET/CT in lymphoma (English)

1 reference

30 August 2017

2

Bruce D Cheson

1 reference

30 August 2017

Lale Kostakoglu

1

1 reference

30 August 2017

publication date

12 February 2014

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

30 August 2017

published in

1 reference

30 August 2017

volume

41

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

1004-1027

1 reference

Revised response criteria for malignant lymphoma

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Prognostic factors in low-grade non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Imaging in staging of malignant lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Limitations of CT during PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Utility of FDG-PET scanning in lymphoma by WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Follicular lymphoma: clinical features and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Integration of FDG-PET/CT into external beam radiation therapy planning: technical aspects and recommendations on methodological approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Does enhanced CT influence the biological GTV measurement on FDG-PET images?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

The role of bone marrow biopsy in Hodgkin lymphoma staging: "to be, or not to be, that is the question"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Positron emission tomography in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Clinical utility of ¹⁸F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

(18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Correlation of hematologic parameters with bone marrow and spleen uptake in FDG PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

The utility of body FDG PET in staging primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Predicting future morphological changes of lesions from radiotracer uptake in 18F-FDG-PET images

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organiza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

FDG PET/CT predictive role in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Salvage therapy for Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Effective doses in radiology and diagnostic nuclear medicine: a catalog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2686-2

Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis

21 January 2018

1 reference

12 December 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

Malignant splenic lymphoma: sonographic patterns, diagnosis and follow-up

1 reference

12 December 2020

Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen

1 reference

12 December 2020

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging

1 reference

12 December 2020

18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.

1 reference

12 December 2020

Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients

1 reference

12 December 2020

Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology

1 reference

12 December 2020

Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials

1 reference

12 December 2020

Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials

1 reference

12 December 2020

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

1 reference

12 December 2020

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma

1 reference

12 December 2020

2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial

1 reference

12 December 2020

Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease

1 reference

12 December 2020

18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT

1 reference

12 December 2020

The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

1 reference

12 December 2020

Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy

1 reference

12 December 2020

Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.

1 reference

12 December 2020

The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma

1 reference

12 December 2020

Report of the Committee on Hodgkin's Disease Staging Procedures

1 reference

12 December 2020

PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.

1 reference

12 December 2020

Extranodal malignant lymphoma: detection with FDG PET versus CT

1 reference

12 December 2020

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease

1 reference

12 December 2020

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

1 reference

12 December 2020

Whole body positron emission tomography in the treatment of Hodgkin disease

1 reference

12 December 2020

Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.

1 reference

12 December 2020

Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and predni

1 reference

12 December 2020

Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma

1 reference

12 December 2020

Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations.

1 reference

12 December 2020

The role of positron emission tomography (PET) in the management of lymphoma patients

1 reference

12 December 2020

F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis

1 reference

12 December 2020

Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission

1 reference

12 December 2020

Detection of lymphoma in bone marrow by whole-body positron emission tomography

1 reference

12 December 2020

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

1 reference

12 December 2020

Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma.

1 reference

12 December 2020

Influence of PET/CT on radiologists and contrast-enhanced CT on nuclear medicine physicians in patients with lymphoma.

1 reference

12 December 2020

Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease

1 reference

12 December 2020

10.1007/S00259-013-2686-2

Identifiers

DOI

1 reference

30 August 2017

1 reference